Suven, with Cohance and more, wants to become a CDMO powerhouse: Annaswamy Vaidheesh, executive chairman
Suven Pharmaceuticals, which announced the proposed merger of Cohance Lifesciences on Thursday, will be investing in research and development, commercial capabilities, and pursuing merger and acquisitions, as it aspires to be the «most admired» fully integrated global contract development and manufacturing organisation (CDMO) services provider, the company's top executive said.
«We want to be a diversified, end-to-end capability outsourcing partner, serving customers from development to commercial scale. Doing this reliably & consistently across a wide range of chemistries, that's where the opportunity is,» said Annaswamy Vaidheesh, executive chairman of Suven in an interview to ET.
«Our business is really about partnering with the customers over the long term. Our success is inextricably linked with our customer's as our business models are hard wired together,» Vaidheesh said. He added that he wants Suven to be the Lonzas of the world. Lonza-based in Basel, Switzerland is a global CDMO powerhouse.
Vaidheesh, a pharma veteran who previously led GSK India operations, and was roped in by Advent to lead Suven Pharma said a lot of energies were spent on getting the right talent, putting in systems and processes, project management, building commercial infrastructure, and investments on R&D to build technology and product capabilities.
Vaidheesh said the focus is on engaging more with customers and increasing requests for quotations (RFQs).
«Since we will be investing in R&D, manufacturing and commercial
